Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation and Depletion (2021 - 2025)

InMed Pharmaceuticals' Depreciation and Depletion history spans 5 years, with the latest figure at $12206.0 for Q2 2025.

  • For Q2 2025, Depreciation and Depletion rose 124.37% year-over-year to $12206.0; the TTM value through Jun 2025 reached $50204.0, up 5.16%, while the annual FY2025 figure was $50204.0, 5.16% up from the prior year.
  • Depreciation and Depletion reached $12206.0 in Q2 2025 per INM's latest filing, roughly flat from $12203.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $14242.0 in Q4 2023 to a low of $4217.0 in Q3 2021.
  • Average Depreciation and Depletion over 5 years is $10249.0, with a median of $11394.5 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: crashed 57.88% in 2024, then skyrocketed 124.37% in 2025.
  • A 5-year view of Depreciation and Depletion shows it stood at $6246.0 in 2021, then grew by 28.98% to $8056.0 in 2022, then soared by 76.79% to $14242.0 in 2023, then fell by 14.27% to $12209.0 in 2024, then fell by 0.02% to $12206.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Depreciation and Depletion are $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024).